Developer docs
API playgroundTry for free, no card

Search company profiles

Metagenomi

Full company profile

uuid00004un

Namestring
Metagenomi
Legal namestring
Metagenomi Therapeutics, Inc.
Websiteurl
metagenomi.co
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Metagenomi Therapeutics is a clinical-stage in vivo genome editing company that uses metagenomics — the sequencing and analysis of genetic material recovered from uncultivated microorganisms in natural environments — combined with proprietary AI/machine learning algorithms to discover novel gene editing systems. Founded in 2018 and headquartered in Emeryville, California, the company has built a proprietary discovery platform that has sequenced 385 trillion base pairs and identified over 20,000 editing systems, including programmable nucleases, ultra-small systems compatible with single-AAV delivery for extrahepatic targets, the smallest known CRISPR base editors, RIGS (RNA-mediated integration / prime editing), and CRISPR-associated transposases (CASTs) for large gene insertions. Its core technical differentiation is sourcing entirely new CRISPR and CRISPR-adjacent systems from nature rather than engineering variants of SpCas9, enabling extrahepatic delivery and edits beyond the reach of first-generation CRISPR.

Metagenomi's lead wholly-owned therapeutic program is MGX-001 for hemophilia A, which has demonstrated curative factor VIII activity in non-human primates with no identifiable off-target editing, with IND/CTA filing expected in Q4 2026 and first-in-human dosing targeted for Q1 2027. The company also has a flagship strategic partnership with Ionis Pharmaceuticals signed November 2022 covering up to eight genetic targets, with an $80 million upfront payment plus milestone and royalty economics. Revenue is derived almost entirely from licensing/collaboration upfronts and milestone payments rather than product sales. Metagenomi completed an initial public offering on Nasdaq under ticker MGX in 2024, raising approximately $100 million; the stock subsequently declined roughly 85% from its IPO price, with market capitalization falling to approximately $46-52 million by mid-2026.

In November 2025 the company underwent a major defensive restructuring: founder/CEO Brian Thomas departed (remaining on the board), President/COO Jian Irish was elevated to CEO, and the workforce was reduced by 25% to extend cash runway to Q4 2027 and concentrate resources on advancing MGX-001 into the clinic. Strategic focus has shifted from broad pipeline build-out toward a single-asset clinical execution posture, with collaboration revenue and one-time licensing fees supplementing — but not yet replacing — the need for additional capital or partnership events.

Short descriptiontext

Metagenomi Therapeutics is a clinical-stage biotech that uses metagenomics and AI/ML to discover novel gene editing systems from uncultivated microorganisms, advancing a lead hemophilia A gene therapy program (MGX-001) and earning milestone and royalty revenue through a flagship Ionis Pharmaceuticals partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene editing therapeutics, metagenomics discovery platform, CRISPR nucleases, genome engineering systems, in vivo gene therapy
Industry2 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Editing Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnerships and Collaborations
TypeLicensing Royalties
Description

Revenue from upfront payments, milestone payments, and royalties from pharmaceutical partnerships such as the Ionis collaboration ($80M upfront plus potential additional milestones)

vcaonline.com
2Clinical Development and Commercialization
TypeOne Time License
Description

Future revenue from advancement of proprietary therapeutic programs into clinical development and potential commercialization of gene editing therapies

in.investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Metagenomi operates a metagenomics-powered discovery platform that mines uncultivated microorganisms to identify novel gene editing systems, producing a modular toolbox of programmable nucleases, base editors, ultra-small systems, RIGS, and CASTs. The company advances these discoveries into in vivo gene editing therapeutics (lead program MGX-001 for hemophilia A) and monetizes them through strategic pharmaceutical collaborations such as the Ionis partnership ($80M upfront plus milestones and royalties).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 64% knockdown of Atxn2 protein in mice after direct AAV injection
+3 more records
Product overview1 text field

Metagenomi is an in vivo genome editing company offering a proprietary modular toolbox of next-generation gene editing systems discovered through metagenomics. The platform includes Programmable Nucleases for site-specific gene targeting, Ultra-Small Systems for AAV delivery beyond the liver, Base Editors for single nucleotide changes, RIGS (RNA Mediated Integration Systems) for prime editing and larger edits, and CRISPR Associated Transposases (CASTs) for large gene integrations. The core discovery platform utilizes AI-enabled screening of millions of nuclease and protein libraries. Lead therapeutic programs include MGX-001 for hemophilia A and the APOC3 collaboration with Ionis for hypertriglyceridemia.

Product and service3 records
1Metagenomics Discovery Platform
CategoryGene Editing Discovery Platform
Description

Proprietary metagenomics-powered discovery platform combining AI/ML with proprietary algorithms to screen metagenomics database for novel CRISPR nucleases and effector enzymes. Used internally to generate gene editing tools for therapeutic development and forms the basis for strategic partnerships.

2MGX-001 Hemophilia A Program
CategoryGene Editing Therapeutic
Description

Lead in vivo gene editing therapeutic program targeting hemophilia A, demonstrating curative factor VIII activity in non-human primates with no identifiable off-target editing. IND filing expected Q4 2026 with patient dosing in Q1 2027.

3APOC3 Program (Ionis Collaboration)
CategoryGene Editing Therapeutic
Description

Collaboration with Ionis Pharmaceuticals targeting APOC3 for severe hypertriglyceridemia, using CRISPR/Cas-mediated knockout as a one-time treatment approach. Part of broader partnership covering up to four genetic targets with potential for four additional.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-11-14
Description

Collaboration to develop gene editing therapies combining Ionis' RNA-targeted technology with Metagenomi's gene editing systems. Initially targeting up to four genetic targets with potential for four additional targets upon achievement of predetermined development milestones. Ionis paid $80 million upfront with potential for additional milestone payments and royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 and in vivo/ex vivo cell therapies. Comparable as a public peer developing in vivo gene editing therapeutics with platform-based discovery and a pipeline of wholly-owned and partnered programs.

TypeEmerging player
Description

Precision BioSciences develops in vivo gene editing using ARCUS meganucleases for genetic diseases and allogeneic CAR-T for oncology. Comparable as a gene editing platform company with both in vivo and ex vivo programs but smaller scale.

TypeDirect peer
Description

Sangamo Therapeutics develops genomic medicines using zinc finger nucleases (ZFNs) and other genome editing platforms, including in vivo programs in hemophilia and other indications. Comparable as an established public gene editing peer pursuing similar therapeutic areas.

TypeDirect peer
Description

Beam Therapeutics is a clinical-stage biotech developing base editing and prime editing therapies. Directly comparable as a public gene editing company pioneering next-generation editing modalities that overlap with Metagenomi's base editor and RIGS platforms.

TypeDirect peer
Description

Verve Therapeutics develops in vivo base editing therapies for cardiovascular disease, including VERVE-101 for heterozygous familial hypercholesterolemia. Directly comparable in pursuing in vivo gene editing for liver/cardiovascular indications with a similar clinical-stage profile.

TypeDirect peer
Description

Editas Medicine develops CRISPR-based gene editing medicines including EDIT-101 and EDIT-301. Directly comparable as a public, clinical-stage gene editing company with a similar scientific founding history and therapeutic focus.

TypeEmerging player
Description

Caribou Biosciences is a clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR Cas12a chRDNA technology. Comparable as a gene editing company but with a primary focus on oncology cell therapy rather than in vivo therapeutics.

TypeDirect peer
Description

Prime Medicine develops prime editing therapies for a range of genetic diseases. Comparable as a public, clinical-stage next-generation gene editing company whose prime editing technology overlaps with Metagenomi's RIGS platform.

TypeDirect peer
Description

CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-based therapies including Casgevy (approved for sickle cell disease and beta-thalassemia). Directly comparable as a public, gene-editing therapeutics company pursuing in vivo and ex vivo indications.

TypeEmerging player
Description

Tessera Therapeutics is developing Gene Writing technology for precise genomic modifications, including large-gene integrations. Comparable as an emerging gene writing/editing platform pursuing similar next-generation capabilities like CAST-mediated integration.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Metagenomi

Gene Editing Therapeuticsmetagenomi.co

Metagenomi Therapeutics is a clinical-stage biotech that uses metagenomics and AI/ML to discover novel gene editing systems from uncultivated microorganisms, advancing a lead hemophilia A gene therapy program (MGX-001) and earning milestone and royalty revenue through a flagship Ionis Pharmaceuticals partnership.

What Metagenomi does

Metagenomi Therapeutics is a clinical-stage in vivo genome editing company that uses metagenomics — the sequencing and analysis of genetic material recovered from uncultivated microorganisms in natural environments — combined with proprietary AI/machine learning algorithms to discover novel gene editing systems. Founded in 2018 and headquartered in Emeryville, California, the company has built a proprietary discovery platform that has sequenced 385 trillion base pairs and identified over 20,000 editing systems, including programmable nucleases, ultra-small systems compatible with single-AAV delivery for extrahepatic targets, the smallest known CRISPR base editors, RIGS (RNA-mediated integration / prime editing), and CRISPR-associated transposases (CASTs) for large gene insertions. Its core technical differentiation is sourcing entirely new CRISPR and CRISPR-adjacent systems from nature rather than engineering variants of SpCas9, enabling extrahepatic delivery and edits beyond the reach of first-generation CRISPR.

Metagenomi's lead wholly-owned therapeutic program is MGX-001 for hemophilia A, which has demonstrated curative factor VIII activity in non-human primates with no identifiable off-target editing, with IND/CTA filing expected in Q4 2026 and first-in-human dosing targeted for Q1 2027. The company also has a flagship strategic partnership with Ionis Pharmaceuticals signed November 2022 covering up to eight genetic targets, with an $80 million upfront payment plus milestone and royalty economics. Revenue is derived almost entirely from licensing/collaboration upfronts and milestone payments rather than product sales. Metagenomi completed an initial public offering on Nasdaq under ticker MGX in 2024, raising approximately $100 million; the stock subsequently declined roughly 85% from its IPO price, with market capitalization falling to approximately $46-52 million by mid-2026.

In November 2025 the company underwent a major defensive restructuring: founder/CEO Brian Thomas departed (remaining on the board), President/COO Jian Irish was elevated to CEO, and the workforce was reduced by 25% to extend cash runway to Q4 2027 and concentrate resources on advancing MGX-001 into the clinic. Strategic focus has shifted from broad pipeline build-out toward a single-asset clinical execution posture, with collaboration revenue and one-time licensing fees supplementing — but not yet replacing — the need for additional capital or partnership events.

Metagenomi firmographics

Firmographics
Name
Metagenomi
Legal name
Metagenomi Therapeutics, Inc.
Website
https://metagenomi.co
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Metagenomi Therapeutics is a clinical-stage biotech that uses metagenomics and AI/ML to discover novel gene editing systems from uncultivated microorganisms, advancing a lead hemophilia A gene therapy program (MGX-001) and earning milestone and royalty revenue through a flagship Ionis Pharmaceuticals partnership.
Ownership category
akta.pro rank

Metagenomi industry classification

Industry
Product category
Gene Editing Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Gene editing therapeutics
  • Metagenomics discovery platform
  • CRISPR nucleases
  • Genome engineering systems
  • In vivo gene therapy

Where Metagenomi is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Metagenomi business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Strategic Partnerships and Collaborations: Revenue from upfront payments, milestone payments, and royalties from pharmaceutical partnerships such as the Ionis collaboration ($80M upfront plus potential additional milestones)
  2. Clinical Development and Commercialization: Future revenue from advancement of proprietary therapeutic programs into clinical development and potential commercialization of gene editing therapies

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Metagenomi product offering

Product offering

Core offering

Metagenomi operates a metagenomics-powered discovery platform that mines uncultivated microorganisms to identify novel gene editing systems, producing a modular toolbox of programmable nucleases, base editors, ultra-small systems, RIGS, and CASTs. The company advances these discoveries into in vivo gene editing therapeutics (lead program MGX-001 for hemophilia A) and monetizes them through strategic pharmaceutical collaborations such as the Ionis partnership ($80M upfront plus milestones and royalties).

Product overview

Metagenomi is an in vivo genome editing company offering a proprietary modular toolbox of next-generation gene editing systems discovered through metagenomics. The platform includes Programmable Nucleases for site-specific gene targeting, Ultra-Small Systems for AAV delivery beyond the liver, Base Editors for single nucleotide changes, RIGS (RNA Mediated Integration Systems) for prime editing and larger edits, and CRISPR Associated Transposases (CASTs) for large gene integrations. The core discovery platform utilizes AI-enabled screening of millions of nuclease and protein libraries. Lead therapeutic programs include MGX-001 for hemophilia A and the APOC3 collaboration with Ionis for hypertriglyceridemia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Metagenomics Discovery Platform Proprietary metagenomics-powered discovery platform combining AI/ML with proprietary algorithms to screen metagenomics database for novel CRISPR nucleases and effector enzymes. Used internally to generate gene editing tools for therapeutic development and forms the basis for strategic partnerships.
  • MGX-001 Hemophilia A Program Lead in vivo gene editing therapeutic program targeting hemophilia A, demonstrating curative factor VIII activity in non-human primates with no identifiable off-target editing. IND filing expected Q4 2026 with patient dosing in Q1 2027.
  • APOC3 Program (Ionis Collaboration) Collaboration with Ionis Pharmaceuticals targeting APOC3 for severe hypertriglyceridemia, using CRISPR/Cas-mediated knockout as a one-time treatment approach. Part of broader partnership covering up to four genetic targets with potential for four additional.

Quantifiable outcome

  • 64% knockdown of Atxn2 protein in mice after direct AAV injection
  • +3 more outcomes

Companies that use Metagenomi

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Metagenomi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Metagenomi partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ionis PharmaceuticalsflagshipStrategic or Co-development Partner · 14 November 2022Collaboration to develop gene editing therapies combining Ionis' RNA-targeted technology with Metagenomi's gene editing systems. Initially targeting up to four genetic targets with potential for four additional targets upon achievement of predetermined development milestones. Ionis paid $80 million upfront with potential for additional milestone payments and royalties.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Metagenomi competitors and assessment

Company assessment

Direct peers

  • Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 and in vivo/ex vivo cell therapies. Comparable as a public peer developing in vivo gene editing therapeutics with platform-based discovery and a pipeline of wholly-owned and partnered programs.
  • Sangamo Therapeutics: Sangamo Therapeutics develops genomic medicines using zinc finger nucleases (ZFNs) and other genome editing platforms, including in vivo programs in hemophilia and other indications. Comparable as an established public gene editing peer pursuing similar therapeutic areas.
  • Beam Therapeutics: Beam Therapeutics is a clinical-stage biotech developing base editing and prime editing therapies. Directly comparable as a public gene editing company pioneering next-generation editing modalities that overlap with Metagenomi's base editor and RIGS platforms.
  • Verve Therapeutics: Verve Therapeutics develops in vivo base editing therapies for cardiovascular disease, including VERVE-101 for heterozygous familial hypercholesterolemia. Directly comparable in pursuing in vivo gene editing for liver/cardiovascular indications with a similar clinical-stage profile.
  • Editas Medicine: Editas Medicine develops CRISPR-based gene editing medicines including EDIT-101 and EDIT-301. Directly comparable as a public, clinical-stage gene editing company with a similar scientific founding history and therapeutic focus.
  • Prime Medicine: Prime Medicine develops prime editing therapies for a range of genetic diseases. Comparable as a public, clinical-stage next-generation gene editing company whose prime editing technology overlaps with Metagenomi's RIGS platform.
  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-based therapies including Casgevy (approved for sickle cell disease and beta-thalassemia). Directly comparable as a public, gene-editing therapeutics company pursuing in vivo and ex vivo indications.

Emerging players

  • Precision BioSciences: Precision BioSciences develops in vivo gene editing using ARCUS meganucleases for genetic diseases and allogeneic CAR-T for oncology. Comparable as a gene editing platform company with both in vivo and ex vivo programs but smaller scale.
  • Caribou Biosciences: Caribou Biosciences is a clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR Cas12a chRDNA technology. Comparable as a gene editing company but with a primary focus on oncology cell therapy rather than in vivo therapeutics.
  • Tessera Therapeutics: Tessera Therapeutics is developing Gene Writing technology for precise genomic modifications, including large-gene integrations. Comparable as an emerging gene writing/editing platform pursuing similar next-generation capabilities like CAST-mediated integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Metagenomi social profiles

Digital presence

Metagenomi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Metagenomi leadership team

Management profile

Number of profiles

Profiles11 records

Metagenomi funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Metagenomi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metagenomi

What does Metagenomi do?

Metagenomi operates a metagenomics-powered discovery platform that mines uncultivated microorganisms to identify novel gene editing systems, producing a modular toolbox of programmable nucleases, base editors, ultra-small systems, RIGS, and CASTs. The company advances these discoveries into in vivo gene editing therapeutics (lead program MGX-001 for hemophilia A) and monetizes them through strategic pharmaceutical collaborations such as the Ionis partnership ($80M upfront plus milestones and royalties).

Is Metagenomi a public or private company?

Metagenomi is a public company. It is classified as public and is currently operating.

When was Metagenomi founded?

Metagenomi was founded in 2019. It employs 101 to 250 people.

Where is Metagenomi based?

Metagenomi is headquartered in Emeryville, United States, in the North America region.

How does Metagenomi make money?

Two revenue lines are on record. Strategic Partnerships and Collaborations are the primary driver. The others are clinical Development and Commercialization.

Who are Metagenomi's main competitors?

Direct peers on record are Intellia Therapeutics, Sangamo Therapeutics, Beam Therapeutics, Verve Therapeutics, Editas Medicine, Prime Medicine and CRISPR Therapeutics. Emerging players are Precision BioSciences, Caribou Biosciences and Tessera Therapeutics.

Does Metagenomi have an API?

No public API is recorded for Metagenomi.

What industry is Metagenomi in?

Metagenomi's product category is Gene Editing Therapeutics. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialMetagenomi Therapeutics, Inc. To Present At The Jefferies Global Healthcare Conference In LondonMetagenomi Therapeutics will present at the Jefferies Global Healthcare Conference in London, with a live webcast available on its website. The company's lead program MGX-001 for hemophilia A has shown preclinical potential for a one-time curative treatment. It plans to expand its pipeline using its proprietary genome-editing capabilities.GlobeNewswireMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in LondonMetagenomi Therapeutics CEO Jian Irish will present at the Jefferies Global Healthcare Conference in London on November 18, 2026. The company's lead program MGX-001 for hemophilia A has shown preclinical potential for a one-time curative treatment. The company plans to expand its pipeline using its proprietary genome editing capabilities.MarketScreenerMetagenomi Gets Investigational Approval for Hemophilia TreatmentMetagenomi Therapeutics received FDA approval for its investigational new drug application for a hemophilia A treatment, MGX-001. Preclinical data in non-human primates showed normal FVIII activity. The company plans to start a global clinical trial in the first half of 2027, aiming for initial data in the second half.MorningstarMetagenomi Gets Investigational Approval for Hemophilia TreatmentMetagenomi Therapeutics received FDA approval for its investigational new drug application for a hemophilia A treatment, MGX-001. Preclinical data in non-human primates showed normal FVIII activity. The company plans to start a global clinical trial in the first half of 2027, aiming for initial data in the second half.MarketWatchMetagenomi Gets Investigational Approval for Hemophilia TreatmentMetagenomi Therapeutics received FDA approval for its investigational new drug application for a hemophilia A treatment, MGX-001. Preclinical data in non-human primates showed normal FVIII activity. The company plans to start a global clinical trial in the first half of 2027, aiming for initial data in the second half.Stock TitanMetagenomi to present MGX-001 preclinical data at ASHMetagenomi Therapeutics will present preclinical data on MGX-001, a one-time gene therapy for hemophilia A, at the ASH meeting. The data support a planned global clinical trial in 2027, subject to regulatory clearance. The therapy aims to provide lifelong protection from bleeding events.Markets DailyMetagenomi Details Hemophilia A Gene-Insertion Plans at Chardan ConferenceMetagenomi CEO Jian Irish detailed its hemophilia A gene-insertion program MGX-001, which uses an AAV-delivered factor VIII DNA template and a lipid nanoparticle to integrate the gene into the albumin locus. Preclinical studies showed factor VIII activity reaching normal ranges, with a planned Phase I/II trial next year. Epicrispr also presented early data on its epigenetic regulation candidate EPI-321 for facioscapulohumeral muscular dystrophy.American Banking and Market NewsMetagenomi Details Hemophilia A Gene-Insertion Plans at Chardan ConferenceEpicrispr and Metagenomi presented gene-regulation and gene-insertion approaches at a Chardan conference. Epicrispr's EPI-321 showed lean muscle gains in six FSHD patients, while Metagenomi's MGX-001 aims to insert a factor VIII gene into the albumin locus. Metagenomi plans a Phase I/II trial next year.Defense WorldErnexa Therapeutics (NASDAQ:ERNA) & Metagenomi (NASDAQ:MGX) Head to Head AnalysisA comparative analysis of small-cap healthcare companies Metagenomi and Ernexa Therapeutics indicates that Metagenomi ranks higher in eight out of fifteen evaluated factors including valuation and risk metrics. Despite having lower revenue than Metagenomi, Ernexa Therapeutics shows higher earnings per share but exhibits significantly greater stock volatility with a beta of 2.63 compared to Metagenomi's 0.69. Analyst consensus suggests both stocks have significant upside potential, though Ernexa's target implies a higher percentage gain, leading analysts to view it as more favorable overall.American Banking and Market NewsReviewing Ernexa Therapeutics (NASDAQ:ERNA) & Metagenomi (NASDAQ:MGX)A comparison of Ernexa Therapeutics and Metagenomi shows Metagenomi beats on 8 of 15 factors, including lower valuation and lower volatility. Ernexa has a higher consensus price target ($30 vs $6) and higher earnings, but Metagenomi is more affordable. Analysts favor Ernexa due to its higher probable upside.